

## Director/PDMR Shareholding

7 March 2025

### Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 6 March 2025, an award of the Company's ordinary shares of \$0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 6 March 2020 and was subject to a three-year performance period. On the third anniversary of grant the award was placed in a two-year holding period. The award vested at the end of that holding period. Application of the performance measures specified at the time of grant resulted in 97% of the AZPSP award vesting and the remaining unvested part lapsing.

Following the reinvestment of dividends accrued during performance and holding periods of the AZPSP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot's beneficial interests in Ordinary Shares changed as detailed in the table below:

<b>PDMR</b>	<b>Ordinary Shares acquired under the AZPSP</b>
Pascal Soriot	89,962

For tax purposes, the fair market value of an Ordinary Share at vest of the AZPSP award was 12,062 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Pascal Soriot
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial	Ordinary Shares of US\$0.25 each in AstraZeneca PLC

	instrument, type of instrument Identification code	GB0009895292				
b)	Nature of the transaction	Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration.				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>89,962</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0	89,962
Price(s)	Volume(s)					
0	89,962					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	6 March 2025				
f)	Place of the transaction	Outside a trading venue				

### **AstraZeneca**

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](https://astrazeneca.com) and follow the Company on social media [@AstraZeneca](https://twitter.com/AstraZeneca)

### **Contacts**

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Adrian Kemp**  
**Company Secretary**  
**AstraZeneca PLC**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).